May 06, 2015
Gilead Sciences Acquires EpiTherapeutics
-- Deal Adds Small Molecule Inhibitors against Targets Involved in Epigenetic Regulation --
EpiTherapeutics has generated a library of first-in-class, selective small molecule inhibitors of epigenetic regulation of gene transcription, in particular histone demethylases. The company’s lead pre-clinical compounds are being studied for the treatment of certain cancers.
“Epigenetics is a promising area of research and the EpiTherapeutics
team is a recognized scientific leader in this field,” said
“EpiTherapeutics has done groundbreaking work in a new therapeutic class
of small molecule inhibitors with broad implications across various
disease states,” said
Investors in EpiTherapeutics are NOVO Seeds,
EpiTherapeutics is developing novel innovative cancer drugs based on
epigenetics, a therapeutic area researched by renowned scientist
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks, uncertainties and other factors, including the risk
that Gilead may be unable to advance EpiTherapeutics’ research programs.
These risks, uncertainties and other factors could cause actual results
to differ materially from those referred to in the forward-looking
statements. The reader is cautioned not to rely on these forward-looking
statements. These and other risks are described in detail in Gilead's
Annual Report on Form 10-K for the year ended
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Gilead Sciences, Inc.
Patrick O'Brien, Investors, 650-522-1936
Nathan Kaiser, Media, 650-522-1853